ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Albany Molecular Research Inc. (AMRI) intends to close its Holywell, Wales, facility, which provides process development and small-scale production of active pharmaceutical ingredients (APIs). AMRI acquired the plant, formerly a company called Excelsyn, in 2010. “The original strategy for the Holywell site has been to act as a conduit between Europe and the U.S.,” CEO William S. Marth says. “However, the site has not been able to do this in a way that maximizes value for our customers and shareholders.” The closure could cost 64 jobs.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter